Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.

Target Oncol 2019 08;14(4):417-421

Huntsman Cancer Institute, University of Utah, 1950 Cir of Hope Dr, Salt Lake City, UT, 84112, USA.

Background: The natural histories of, and treatment options for, epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers (NSCLCs) are distinctly different from those of lung cancer that lacks actionable mutations. Ipilimumab is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor that has been approved in other malignancies.

Objective: A phase I trial of ipilimumab plus targeted therapy with either erlotinib or crizotinib was performed to assess the safety of the combination in patients with EGFR-mutated or ALK-rearranged advanced NSCLC.

Methods: Patients with EGFR-mutated or ALK-rearranged NSCLC on a stable dose of erlotinib or crizotinib for > 28 days were eligible for the study. Patients were treated with ipilimumab 3 mg/kg for four cycles plus erlotinib or crizotinib.

Results: Treatment of the EGFR cohort resulted in dose-limiting toxicity in three of eight patients, with grade 3 diarrhea. The protocol was amended to reduce the ipilimumab dose to 1 mg/kg. Excessive toxicity resulted in the study being closed after 14 patients. Four of 11 EGFR-mutated patients ultimately developed grade 3 colitis. Of three ALK-rearranged patients, one developed hypophysitis and another grade 2 pneumonitis. For 11 EGFR-mutated patients, progression-free survival (PFS) from the start of ipilimumab was 17.9 months. Erlotinib treatment began a median 7.7 months before ipilimumab; therefore, erlotinib PFS was 27.8 months. Median overall survival (OS) has not been reached but will be > 42.3 months from erlotinib initiation. For three ALK-rearranged patients, ipilimumab PFS was 24.1 months. Median OS has not been reached but will be at least 47.2 months from the initiation of crizotinib.

Conclusion: Erlotinib plus ipilimumab caused excessive short-term gastrointestinal toxicity leading to early study closure. However, PFS and OS were notable; therefore, targeted therapies with immunotherapy in NSCLC merit further study. Clinicaltrials.gov registration number: NCT01998126.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00658-0DOI Listing
August 2019
7 Reads

Publication Analysis

Top Keywords

patients egfr-mutated
12
ipilimumab
9
patients
9
egfr-mutated patients
8
erlotinib crizotinib
8
reached will
8
three alk-rearranged
8
alk-rearranged patients
8
egfr-mutated alk-rearranged
8
phase trial
8
erlotinib
7
egfr-mutated
5
alk-rearranged
5
study closed
4
toxicity study
4
closed patients
4
ipilimumab dose
4
1 mg/kg excessive
4
dose 1 mg/kg
4
excessive toxicity
4

References

(Supplied by CrossRef)

R Rosell et al.
Lancet Oncol 2012

DR Camidge et al.
Lancet Oncol 2012

JC Soria et al.
N Engl J Med 2018

S Peters et al.
N Engl J Med 2017

CK Lee et al.
Thorac Oncol 2017

JF Gainor et al.
Clin Cancer Res 2016

M Reck et al.
Lancet Respir Med 2019

FS Hodi et al.
N Engl J Med 2010

HJ Hammers et al.
J Clin Oncol 2017

SC Wei et al.
Cell 2017

C Tourneau Le et al.
J Natl Cancer Inst 2009

Similar Publications